Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma

S. Bringhen, M. D'Agostino, L. De Paoli, V. Montefusco, A.M. Liberati, P. Galieni, S. Grammatico, V.E. Muccio, F. Esma, C. De Angelis, P. Musto, S. Ballanti, M. Offidani, M.T. Petrucci, G. Gaidano, P. Corradini, A. Palumbo, P. Sonneveld, M. Boccadoro

Research output: Contribution to journalArticle

Original languageUndefined/Unknown
Pages (from-to)979-985
Number of pages7
JournalLeukemia
Volume32
Issue number4
DOIs
Publication statusPublished - 2018

Cite this

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. / Bringhen, S.; D'Agostino, M.; De Paoli, L.; Montefusco, V.; Liberati, A.M.; Galieni, P.; Grammatico, S.; Muccio, V.E.; Esma, F.; De Angelis, C.; Musto, P.; Ballanti, S.; Offidani, M.; Petrucci, M.T.; Gaidano, G.; Corradini, P.; Palumbo, A.; Sonneveld, P.; Boccadoro, M.

In: Leukemia, Vol. 32, No. 4, 2018, p. 979-985.

Research output: Contribution to journalArticle

Bringhen, S, D'Agostino, M, De Paoli, L, Montefusco, V, Liberati, AM, Galieni, P, Grammatico, S, Muccio, VE, Esma, F, De Angelis, C, Musto, P, Ballanti, S, Offidani, M, Petrucci, MT, Gaidano, G, Corradini, P, Palumbo, A, Sonneveld, P & Boccadoro, M 2018, 'Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma', Leukemia, vol. 32, no. 4, pp. 979-985. https://doi.org/10.1038/leu.2017.327
Bringhen, S. ; D'Agostino, M. ; De Paoli, L. ; Montefusco, V. ; Liberati, A.M. ; Galieni, P. ; Grammatico, S. ; Muccio, V.E. ; Esma, F. ; De Angelis, C. ; Musto, P. ; Ballanti, S. ; Offidani, M. ; Petrucci, M.T. ; Gaidano, G. ; Corradini, P. ; Palumbo, A. ; Sonneveld, P. ; Boccadoro, M. / Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. In: Leukemia. 2018 ; Vol. 32, No. 4. pp. 979-985.
@article{15d9aecfeff24a1191eda03402f52df3,
title = "Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma",
author = "S. Bringhen and M. D'Agostino and {De Paoli}, L. and V. Montefusco and A.M. Liberati and P. Galieni and S. Grammatico and V.E. Muccio and F. Esma and {De Angelis}, C. and P. Musto and S. Ballanti and M. Offidani and M.T. Petrucci and G. Gaidano and P. Corradini and A. Palumbo and P. Sonneveld and M. Boccadoro",
note = "cited By 5",
year = "2018",
doi = "10.1038/leu.2017.327",
language = "Non definita",
volume = "32",
pages = "979--985",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma

AU - Bringhen, S.

AU - D'Agostino, M.

AU - De Paoli, L.

AU - Montefusco, V.

AU - Liberati, A.M.

AU - Galieni, P.

AU - Grammatico, S.

AU - Muccio, V.E.

AU - Esma, F.

AU - De Angelis, C.

AU - Musto, P.

AU - Ballanti, S.

AU - Offidani, M.

AU - Petrucci, M.T.

AU - Gaidano, G.

AU - Corradini, P.

AU - Palumbo, A.

AU - Sonneveld, P.

AU - Boccadoro, M.

N1 - cited By 5

PY - 2018

Y1 - 2018

U2 - 10.1038/leu.2017.327

DO - 10.1038/leu.2017.327

M3 - Articolo

VL - 32

SP - 979

EP - 985

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -